

BAXTER INTERNATIONAL INC.
GAAP Key Product Line Sales
Periods Ending December 31, 2011 and 2010
(unaudited)
(\$ in millions)

| | GAAP Q4 2011 | GAAP Q4 2010 | % Growth @ Actual Rates | % Growth @ Constant Rates | GAAP YTD 2011 | GAAP YTD 2010 | % Growth @ Actual Rates | % Growth @ Constant Rates |
|--|-----------------|-----------------|----------------------------|------------------------------|------------------|------------------|----------------------------|------------------------------|
| BioScience | | | | | | | | |
| Recombinants | \$578 | \$534 | 8% | 7% | \$2,212 | \$2,095 | 6% | 3% |
| Plasma Proteins | 397 | 416 | (4%) | (2%) | 1,440 | 1,368 | 5% | 5% |
| Antibody Therapy | 406 | 386 | 5% | 6% | 1,541 | 1,354 | 14% | 13% |
| Regenerative Medicine | 150 | 145 | 3% | 3% | 580 | 527 | 10% | 8% |
| Other ¹ | 44 | 52 | (16%) | (25%) | 280 | 296 | (6%) | (15%) |
| Total BioScience | \$1,575 | \$1,533 | 3% | 3% | \$6,053 | \$5,640 | 7% | 5% |
| Medical Products ² | | | | | | | | |
| Renal | \$664 | \$626 | 6% | 5% | \$2,530 | \$2,389 | 6% | 2% |
| Global Injectables | 487 | 499 | (2%) | (3%) | 2,004 | 1,891 | 6% | 3% |
| IV Therapies | 469 | 452 | 4% | 4% | 1,802 | 1,678 | 7% | 5% |
| Infusion Systems ³ | 235 | 230 | 2% | 2% | 901 | 655 | 38% | 35% |
| Anesthesia | 147 | 141 | 4% | 4% | 537 | 525 | 2% | 1% |
| Other | 11 | 8 | 33% | 2% | 30 | 19 | 56% | 8% |
| Total Medical Products ³ | \$2,013 | \$1,956 | 3% | 2% | \$7,804 | \$7,157 | 9% | 6% |
| Transfusion Therapies ⁴ | \$6 | \$9 | (33%) | (33%) | \$36 | \$46 | (22%) | (21%) |
| Total Baxter ³ | \$3,594 | \$3,498 | 3% | 3% | \$13,893 | \$12,843 | 8% | 6% |

¹ Principally includes vaccines and sales of plasma to third parties.

² Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

³ GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 18 for a reconciliation to GAAP measures.

⁴ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.